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1. INTRODUCTION {#iid3319-sec-0050}
===============

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a β coronavirus with envelope and 60 to 140 nm in diameter, which is a global urgent public health concern because of its alarmingly high infection rates. SARS‐CoV‐2 contributes to the decrease of lymphocytes, the increase of the level of C‐reactive protein, and the secretion of a large number of inflammatory factors causing cytokine storm. It can lead to multiple organ failure in severe cases.[^1^](#iid3319-bib-0001){ref-type="ref"} However, there is no specific treatment in clinic. The previous view suggests that infants are not at a higher risk for severe coronavirus disease 2019 (COVID‐19) pneumonia.[^2^](#iid3319-bib-0002){ref-type="ref"}, [^3^](#iid3319-bib-0003){ref-type="ref"}, [^4^](#iid3319-bib-0004){ref-type="ref"} We herein report two infant cases with COVID‐19 in Yichang, Hubei, China.

2. CASE PRESENTATION {#iid3319-sec-0060}
====================

The patients have been living with their own families in different districts. Patient 1 is the youngest infant diagnosed with Covid‐19 infection in a hospital in Yichang. The summary of their clinical characteristics and treatment is shown in Table [1](#iid3319-tbl-0001){ref-type="table"}. Laboratory test results are shown in Table [2](#iid3319-tbl-0002){ref-type="table"}. Their chest computed tomographic (CT) images obtained on admission showed bilateral patchy ground glass opacities (Figure [1](#iid3319-fig-0001){ref-type="fig"}). Informed consent was obtained from their parents or guardians for the publication of their clinical data.

###### 

Characteristics of two infants hospitalized with COVID‐19 pneumonia

  Characteristic                             Patient 1                                                                            Patient 2
  ------------------------------------------ ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------
  Age, mo                                    5                                                                                    7
  Sex                                        Male                                                                                 Female
  Birth weight, kg                           3.04                                                                                 3.35
  The general situation at birth             Premature delivery and no asphyxia                                                   Full‐term delivery and no asphyxia
  Mode of birth                              Cesarean section                                                                     Cesarean section
  Growth assessment                          Average                                                                              Above average
  Onset time                                 2020/1/27                                                                            2020/2/4
  Exposure to source of transmission         Visited Wuhan 11 d before onset                                                      Contacted with a neighbor confirmed with NICP
  Characters of other family members         Grandmother was diagnosed with severe NCIP; father and grandfather both have cough   Mother, father, grandmother, and grandfather were all diagnosed with NCIP
  Symptoms on admission                      Cough, poor appetite (6 d), fever (1 d)                                              Fever
  The highest temperature on admission, °C   37.9                                                                                 39.5
  Mental reaction                            Normal                                                                               Normal
  Coinfections                               Not detected                                                                         Mycoplasma pneumoniae
  Treatment                                                                                                                       
  Interferon atomization                     Yes                                                                                  Yes
  Antivirals                                 Ribavirin, Abidol                                                                    Ribavirin, Abidol, and Oseltamivir
  Antibiotics                                Amoxicillin clavulanate potassium                                                    Amoxicillin clavulanate potassium and roxithromycin
  Intravenous immune globulin                10 g/d (days 1‐3)                                                                    10 g/d (day 1)[^a^](#iid3319-tbl1-note-0002){ref-type="fn"}
  Glucocorticoids                            No                                                                                   No
  Fever duration, d                          0                                                                                    10
  Viral duration, d                          18                                                                                   27
  Hospitalization, d                         15                                                                                   30

Abbreviations: COVID‐19, coronavirus disease 2019; NCIP, 2019‐nCoV--infected pneumonia.

Discontinued because of allergic reaction.
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###### 

Main laboratory findings on admission of two infants hospitalized with COVID‐19 pneumonia

  Laboratory data on admission (reference range[^a^](#iid3319-tbl2-note-0002){ref-type="fn"})   Patient 1                                           Patient 2
  --------------------------------------------------------------------------------------------- --------------------------------------------------- -----------
  White blood cell count (3.5‐9.5 × 10^9^/L)                                                    7.92                                                8.52
  Neutrophil count (1.8‐6.3 × 10^9^/L)                                                          0.91                                                5.49
  Lymphocyte count (1.1‐3.2 × 10^9^/L)                                                          6.09[^b^](#iid3319-tbl2-note-0003){ref-type="fn"}   1.84
  Platelet count (125‐350 × 10^9^/L)                                                            506                                                 288
  Hemoglobin (13.0‐17.5 g/dL)                                                                   12.3                                                10.7
  C‐reactive protein (0‐10 mg/L)                                                                2                                                   \<0.499
  Erythrocyte sedimentation rate (0‐20 mm/h)                                                    23                                                  29
  Procalcitonin (\<0.05 ng/mL)                                                                  \<0.05                                              0.12
  Lactate dehydrogenase (120‐250 U/L)                                                           407                                                 274
  Creatine kinase (40‐200 U/L)                                                                  135                                                 123
  Creatine kinase‐MB (0‐25 U/L)                                                                 28                                                  25
  Alanine aminotransferase (9‐50 U/L)                                                           63                                                  48
  Aspartate aminotransferase (15‐40 U/L)                                                        66                                                  62
  Total bilirubin (6.5‐8.5 g/dL)                                                                5.6                                                 5.9
  Globulin (2.0‐4.0 g/dL)                                                                       1.8                                                 1.7
  Urea nitrogen (8.0‐22.0 mg/dL[^c^](#iid3319-tbl2-note-0004){ref-type="fn"})                   5.4                                                 9.7
  Creatinine (0.64‐1.10 mg/dL[^d^](#iid3319-tbl2-note-0005){ref-type="fn"})                     0.2                                                 0.24
  IgG (7‐16 g/L)                                                                                5.91                                                ...
  IgA (0.7‐4 g/L)                                                                               0.35                                                ...
  D‐dimer (0‐0.05 mg/L)                                                                         0.4                                                 0.35

Abbreviations: COVID‐19, coronavirus disease 2019; IgA, immunoglobulin A; IgG, Immunoglobulin G; MB, muscle and brain type.

Reference ranges used at Yichang Central People\'s Hospital for general adults. They may not all be appropriate for children.

It could be a physiological situation that lymphocyte count of infants before half a year old is significantly higher than the normal value, which may be related to the development of the immune system during this period.

To convert the values for urea nitrogen to millimoles per liter, multiply by 0.357.

To convert the values for creatinine to micromoles per liter, multiply by 88.4.
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![A, The chest computed tomography (CT) of patient 1 showed multiple patchy ground glass opacity shadows in both lungs, and local interlobular septum thickening like a grid. B, The chest CT of patient 2 showed extensive fusion with patchy blurred shadows in both lungs](IID3-8-380-g001){#iid3319-fig-0001}

3. DISCUSSION {#iid3319-sec-0070}
=============

Since 30 January 2020, a total of 47 children (≤12 years of age) with fever, respiratory symptoms, and lung CT suspected viral infection were hospitalized in Yichang Central People\'s Hospital, of which five were diagnosed with 2019‐nCoV--infected pneumonia (10.6%). All five were from familial clusters. There were at least three to four family members in close contact with the highly suspected or confirmed cases of COVID‐19. So far, all the children have recovered and have been discharged from the hospital.

The two infants presented varying degrees of increase in lactate dehydrogenase and aspartate aminotransferase. We treated them with agents to protect hepatocytes and cardiomyocytes. There is no specific antiviral drug for the treatment of infants with COVID‐19. In our cases, we use three kinds of antivirals for the treatment of COVID‐19 infants for 8 days. And the viral duration of these infants were 18 and 27, respectively. The heart function of infants are impaired, which predict a poor prognosis. One of our cases coinfected with *Mycoplasma pneumonia* has a relative longer duration of symptom release, viral duration, and hospitalization than the other infants who do not. Therefore, the coinfection of COVID‐19 infants should be taken seriously.

The current clinical data show that pregnant women, children, and infants are susceptible to SARS‐CoV‐2. The clinical manifestations of most children are relatively mild. Some children will gradually develop fever, fatigue, dry cough, nasal congestion, runny nose, and other upper respiratory symptoms 3 to 7 days after infection.[^2^](#iid3319-bib-0002){ref-type="ref"} Some children just have digestive tract symptoms such as diarrhea, nausea, and vomiting while showing no symptoms of fever or pneumonia.[^3^](#iid3319-bib-0003){ref-type="ref"} Most of them recover within 2 weeks and have good prognosis.[^3^](#iid3319-bib-0003){ref-type="ref"} But a small number of children may progress to lower respiratory tract infection. Although there was only one death---a 10‐month‐old infant with intussusception died of multiorgan failure---as recorded.[^4^](#iid3319-bib-0004){ref-type="ref"} Therefore, the potential risk of death in COVID‐19 infection in infants cannot be ignored, especially when combined with serious or congenital disease.

Also, there are high incidences of influenza, respiratory syncytial virus, and other respiratory infectious diseases in spring. Clinicians are supposed to recognize the possibility of other virus or bacteria, mycoplasma, and other coinfections.
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